{"filing":{"accession_number":"0001129928-26-000057","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"oncy-20260928.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000057/oncy-20260928.htm"},"events":[{"id":35370,"run_id":32575,"accession_number":"0001129928-26-000057","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces clinical trial progress on REO 033, a randomized colorectal cancer study, including site activation completion, enrollment acceleration, and FDA alignment on a potential accelerated approval pathway. This is a material operational/clinical milestone for a clinical-stage biotech company, but does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. The event is clearly operational (clinical development progress) rather than financial, governance, legal, or existential in nature.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39403,"accession_number":"0001129928-26-000057","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical trial progress on REO 033, a randomized colorectal cancer study, including site activation completion, enrollment acceleration, and FDA alignment on a potential accelerated approval pathway. This is a material operational/clinical milestone for a clinical-stage biotech company, but does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. The event is clearly operational (clinical development progress) rather than financial, governance, legal, or existential in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T13:32:46.250853+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39403,"accession_number":"0001129928-26-000057","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical trial progress on REO 033, a randomized colorectal cancer study, including site activation completion, enrollment acceleration, and FDA alignment on a potential accelerated approval pathway. This is a material operational/clinical milestone for a clinical-stage biotech company, but does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. The event is clearly operational (clinical development progress) rather than financial, governance, legal, or existential in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T13:32:46.250853+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-09-28"}]}